Viracta Therapeutics Inc (NAS:VIRX)

$ 0.186 -0.0017 (-0.91%) Market Cap: 7.39 Mil Enterprise Value: 3.17 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

Viracta Therapeutics Inc To Host R&D Day Transcript
Oct 04, 2023
Viracta Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Viracta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023
Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call Transcript
Apr 27, 2022
Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call Transcript
Nov 30, 2020
Q3 2020 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Nov 16, 2020

Earnings
Q2 2020 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2020

Earnings
Q1 2020 Sunesis Pharmaceuticals Inc Earnings Call Transcript
May 07, 2020

Earnings
Q4 2019 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Mar 10, 2020

Earnings
Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 13, 2019
Q3 2019 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Nov 12, 2019

Earnings
Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Aug 07, 2019

Earnings
Q1 2019 Sunesis Pharmaceuticals Inc Earnings Call Transcript
May 08, 2019

Earnings
Sunesis Pharmaceuticals Inc at Oppenheimer Healthcare Conference Transcript
Mar 19, 2019
Q4 2018 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Mar 07, 2019

Earnings

Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call Transcript

Nov 30, 2020 / 01:30PM GMT

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Sunesis Pharmaceuticals and Viracta Therapeutics joint conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today to Mr. Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. Thank you. Please go ahead.

Dayton Misfeldt

Sunesis Pharmaceuticals, Inc. - Principal Financial Officer, Secretary, Interim CEO & Director

Thank you, Dylan. Good morning, and thank you for joining us today to discuss the proposed transaction between Sunesis and Viracta. Today, we will be making prepared remarks and will not be taking questions. Joining me on the call this morning is Dr. Ivor Royston, President and Chief Executive Officer of Viracta.

Please note, in addition to the press release issued this morning announcing the transaction, we have included a slide presentation in the webcast of today's call to accompany today's prepared remarks.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.